<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069095</url>
  </required_header>
  <id_info>
    <org_study_id>NO16966</org_study_id>
    <nct_id>NCT00069095</nct_id>
  </id_info>
  <brief_title>A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (&quot;XELOX&quot;) With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) (&quot;FOLFOX-4&quot;) With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or
      intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with
      or without iv bevacizumab (Avastin), as a first-line treatment in patients with metastatic
      colorectal cancer. Patients were randomized to receive 1) XELOX (Xeloda 1000 mg/m^2 orally
      [po] twice a day [bid] on Days 1-15 + oxaliplatin in 3 week cycles), 2) FOLFOX-4 (oxaliplatin
      + leucovorin + fluorouracil [5-FU] in 2 week cycles), 3) XELOX + bevacizumab (7.5 mg iv on
      Day 1 in 3 week cycles), or 4) FOLFOX-4 + bevacizumab (5 mg iv on Day 1 in 2 week cycles).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted in 2 parts: An initial 2-arm part in which patients were randomized
      to 1 of 2 different treatment groups (XELOX or FOLFOX-4), and a subsequent 2 x 2 factorial
      part, added to the study through a protocol amendment, in which additional patients were
      randomized into one of 4 different treatment groups (XELOX + placebo, FOLFOX-4 + placebo,
      XELOX + bevacizumab, or FOLFOX-4 + bevacizumab). Due to the comparison of the oral agent
      capecitabine with bolus and infused fluorouracil, the study was not blinded with respect to
      these 2 treatments. The study was double-blind with regard to the administration of
      bevacizumab, ie, there was a placebo control for bevacizumab in the second part of the study.

      The study consisted of 3 phases, a Primary Study Treatment Phase, a Post-Study Treatment
      Phase, and a Follow-Up Phase.

      Primary Study Treatment Phase

      Patients were to receive up to 16 cycles (2-arm part of the study) or 24 cycles (4-arm part
      of the study) of treatment during the Primary Study Treatment Phase (48 weeks).

      Post-Study Treatment Phase

      Patients who completed the 48-week primary study treatment phase without progressive disease
      were eligible to enter the post-study treatment phase at the discretion of the investigator
      and the sponsor. Patients who entered this phase were to continue treatment on the same
      regimen to which they were initially randomized until either progression of disease was
      documented, unacceptable toxicity occurred, or the patient withdrew consent.

      Follow-up Phase

      Patients who terminated study treatment during the primary or post-study treatment phase were
      followed until disease progression or death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
    <description>Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>Week 1 to Week 54</time_frame>
    <description>For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>Week 1 to Week 54</time_frame>
    <description>For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</measure>
    <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
    <description>For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2035</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX (oxaliplatin+capecitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the 2-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX (oxaliplatin+capecitabine) + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the 4-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the 2-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the 4-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin 130 mg/m^2</intervention_name>
    <description>Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.</description>
    <arm_group_label>XELOX (oxaliplatin+capecitabine)</arm_group_label>
    <arm_group_label>XELOX (oxaliplatin+capecitabine) + bevacizumab</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine 1000 mg/m^2</intervention_name>
    <description>Capecitabine was taken within 30 min after the end of breakfast and dinner.</description>
    <arm_group_label>XELOX (oxaliplatin+capecitabine)</arm_group_label>
    <arm_group_label>XELOX (oxaliplatin+capecitabine) + bevacizumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab 7.5 mg/kg</intervention_name>
    <description>Bevacizumab was administered in a 30 to 90 min infusion.</description>
    <arm_group_label>XELOX (oxaliplatin+capecitabine) + bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for bevacizumab 7.5 mg/kg</intervention_name>
    <description>Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.</description>
    <arm_group_label>XELOX (oxaliplatin+capecitabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin 85 mg/m^2</intervention_name>
    <description>Oxaliplatin 85 mg/m^2 was administered simultaneously with leucovorin in a 2 h infusion.</description>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)</arm_group_label>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin 200 mg/m^2</intervention_name>
    <description>Leucovorin was administered simultaneously with oxaliplatin 85 mg/m^2 in a 2 h infusion.</description>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)</arm_group_label>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil 400 mg/m^2</intervention_name>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)</arm_group_label>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab</arm_group_label>
    <other_name>Efudex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab 5 mg/kg</intervention_name>
    <description>Bevacizumab was administered in a 30 to 90 min infusion.</description>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for bevacizumab 5 mg/kg</intervention_name>
    <description>Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.</description>
    <arm_group_label>FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients ≥ 18 years of age.

          -  Metastatic colorectal cancer.

          -  ≥ 1 target lesion.

        Exclusion Criteria:

          -  Previous treatment with oxaliplatin or bevacizumab.

          -  Previous systemic chemotherapy or immunotherapy for advanced or metastatic disease.

          -  Progressive disease during or within 6 months of completion of previous adjuvant
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gilroy</city>
        <state>California</state>
        <zip>95020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>33610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7828</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Footscray</city>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurralta Park</city>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Macquarie</city>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>JAÚ</city>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7L 2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangdong</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jiangsu</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jiangxi</city>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shandong</city>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chomutov</city>
        <zip>430 12</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 36</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulogne-billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chambray Les Tours</city>
        <zip>37171</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metz</city>
        <zip>57072</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Herblain</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala</city>
        <zip>01009</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>H-1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyor</city>
        <zip>9002</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <zip>60121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-170</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beja</city>
        <zip>7801-849</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117837</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <zip>7506</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandton</city>
        <zip>2199</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leganes</city>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gaevle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Västerås</city>
        <zip>72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kueishan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34300</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Derby</city>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO9 4PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Panama</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2003</study_first_submitted>
  <study_first_submitted_qc>September 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2003</study_first_posted>
  <results_first_submitted>December 11, 2015</results_first_submitted>
  <results_first_submitted_qc>December 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 22, 2016</results_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in 32 countries - Australia, Austria, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Mexico, New Zealand, Norway, Panama, Portugal, Russia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey and USA.</recruitment_details>
      <pre_assignment_details>A total of 2035 participants were randomized to any one of the treatment groups in the study (634 participants in the initial 2-arm part and 1401 participants in the 2x2 factorial part of the study), but only 2034 received study treatment as 1 participant was enrolled twice in the study at 2 study centers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Xelox</title>
          <description>Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="P2">
          <title>Folfox-4</title>
          <description>Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="P3">
          <title>Xelox+P</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for bevacizumab (BV) [volume equivalent to 7.5 mg/kg BV] over 30 to 90 minutes followed by oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="P4">
          <title>Folfox-4+P</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for BV (volume equivalent to 5 mg/kg BV) over 30 to 90 minutes followed by oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="P5">
          <title>Xelox+BV</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 7.5 mg/kg over 30 to 90 minutes followed by oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="P6">
          <title>Folfox-4+BV</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 5 mg/kg over 30 to 90 minutes followed by oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
                <participants group_id="P2" count="317"/>
                <participants group_id="P3" count="350"/>
                <participants group_id="P4" count="351"/>
                <participants group_id="P5" count="350"/>
                <participants group_id="P6" count="349"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="302"/>
                <participants group_id="P3" count="314"/>
                <participants group_id="P4" count="320"/>
                <participants group_id="P5" count="302"/>
                <participants group_id="P6" count="301"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Admin/Other</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="109"/>
                <participants group_id="P6" count="101"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="175"/>
                <participants group_id="P4" count="154"/>
                <participants group_id="P5" count="101"/>
                <participants group_id="P6" count="102"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-study Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P2" count="13">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P3" count="21">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P4" count="17">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P5" count="36">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P6" count="29">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligible for surgery</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant refusal/Admin reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant had complete response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>More than 21 days delay between cycles</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision (enough treatment)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant will start new treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant wanted break from treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant completed treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant had progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant/Physician decision to stop</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Preplanned 6 cycles after surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="284">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P2" count="299">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P3" count="298">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P4" count="299">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P5" count="278">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
                <participants group_id="P6" count="272">Participants could enter the follow-up phase even without entering the post-study treatment phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="178"/>
                <participants group_id="P4" count="187"/>
                <participants group_id="P5" count="186"/>
                <participants group_id="P6" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="101"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="101"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were described for the Intent-to-treat (ITT) population.This population included all randomized participants who provided written informed consent.</population>
      <group_list>
        <group group_id="B1">
          <title>Xelox</title>
          <description>Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="B2">
          <title>Folfox-4</title>
          <description>Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="B3">
          <title>Xelox+P</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for bevacizumab (BV) [volume equivalent to 7.5 mg/kg BV] over 30 to 90 minutes followed by oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="B4">
          <title>Folfox-4+P</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for BV (volume equivalent to 5 mg/kg BV) over 30 to 90 minutes followed by oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="B5">
          <title>Xelox+BV</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 7.5 mg/kg over 30 to 90 minutes followed by oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="B6">
          <title>Folfox-4+BV</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 5 mg/kg over 30 to 90 minutes followed by oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="317"/>
            <count group_id="B2" value="317"/>
            <count group_id="B3" value="350"/>
            <count group_id="B4" value="351"/>
            <count group_id="B5" value="350"/>
            <count group_id="B6" value="349"/>
            <count group_id="B7" value="2034"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="10.76"/>
                    <measurement group_id="B2" value="60.6" spread="10.94"/>
                    <measurement group_id="B3" value="59.1" spread="12.14"/>
                    <measurement group_id="B4" value="58.8" spread="10.87"/>
                    <measurement group_id="B5" value="59.7" spread="11.28"/>
                    <measurement group_id="B6" value="59.7" spread="10.74"/>
                    <measurement group_id="B7" value="59.7" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="165"/>
                    <measurement group_id="B5" value="137"/>
                    <measurement group_id="B6" value="144"/>
                    <measurement group_id="B7" value="827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="205"/>
                    <measurement group_id="B4" value="186"/>
                    <measurement group_id="B5" value="213"/>
                    <measurement group_id="B6" value="205"/>
                    <measurement group_id="B7" value="1207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The eligible patient population (EPP) excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.</description>
          <population>The eligible patient population (EPP) excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="245" upper_limit="268"/>
                    <measurement group_id="O2" value="241" lower_limit="229" upper_limit="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence of treatment arm A (‘XELOX’) to treatment arm B (‘FOLFOX-4’) was tested via the following hypotheses - H0: HRA/B &gt;/= 1.23 versus H1: HRA/B &lt; 1.23. HRA/B denotes the hazard of disease progression or death under treatment A (‘XELOX’) divided by the hazard of disease progression or death under treatment B (‘FOLFOX-4’).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was demonstrated if the upper limit of the 2-sided 97.5% confidence interval (CI) for the hazard ratio (HR) was less than the predefined limit of 1.23 (the non-inferiority margin). A stratified Cox model was used. In order to retain an experiment-wise two-sided type I error of 5%, the non-inferiority analysis for PFS used a two-sided significance level of 2.5%.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.0" lower_limit="281" upper_limit="319"/>
                    <measurement group_id="O2" value="261.0" lower_limit="246" upper_limit="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence of treatment arm A (‘XELOX’) to treatment arm B (‘FOLFOX-4’) was tested via the following hypotheses - H0: HRA/B &gt;/= 1.23 versus H1: HRA/B &lt; 1.23. HRA/B denotes the hazard of disease progression or death under treatment A (‘XELOX’) divided by the hazard of disease progression or death under treatment B (‘FOLFOX-4’).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was demonstrated if the upper limit of the 2-sided 97.5% confidence interval (CI) for the hazard ratio (HR) was less than the predefined limit of 1.23 (the non-inferiority margin). A stratified Cox model was used. In order to retain an experiment-wise two-sided type I error of 5%, the non-inferiority analysis for PFS used a two-sided significance level of 2.5%.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.0" lower_limit="244" upper_limit="278"/>
                    <measurement group_id="O2" value="335.0" lower_limit="310" upper_limit="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.0" lower_limit="252" upper_limit="290"/>
                    <measurement group_id="O2" value="234.0" lower_limit="221" upper_limit="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HRs and 97.5% confidence interval were reported for treatment arm A (XELOX/XELOX+P/XELOX+BV) versus treatment arm B (FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Fewer events were expected in the ‘on-treatment analysis’, thus leading to reduced power. No formal statistical testing was therefore applied.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.0" lower_limit="227" upper_limit="254"/>
                    <measurement group_id="O2" value="316.0" lower_limit="294" upper_limit="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.0" lower_limit="247" upper_limit="270"/>
                    <measurement group_id="O2" value="244.0" lower_limit="230" upper_limit="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence of treatment arm A (‘XELOX’) to treatment arm B (‘FOLFOX-4’) was tested via the following hypotheses - H0: HRA/B &gt;/= 1.23 versus H1: HRA/B &lt; 1.23. HRA/B denotes the hazard of disease progression or death under treatment A (‘XELOX’) divided by the hazard of disease progression or death under treatment B (‘FOLFOX-4’).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was demonstrated if the upper limit of the 2-sided 97.5% confidence interval (CI) for the hazard ratio (HR) was less than the predefined limit of 1.23 (the non-inferiority margin). A stratified Cox model was used. In order to retain an experiment-wise two-sided type I error of 5%, the non-inferiority analysis for PFS used a two-sided significance level of 2.5%.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.0" lower_limit="230" upper_limit="258"/>
                    <measurement group_id="O2" value="287.0" lower_limit="276" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549.0" lower_limit="528" upper_limit="576"/>
                    <measurement group_id="O2" value="577.0" lower_limit="535" upper_limit="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HRs and 97.5% confidence interval were reported for treatment arm A (XELOX/XELOX+P/XELOX+BV) versus treatment arm B (FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study was not powered for testing non-inferiority of XELOX vs FOLFOX-4 with respect to overall survival and no margin could be derived following the effect retention concept. The same margins used for the PFS analysis [Non-inferiority was demonstrated if the upper limit of the 2-sided 97.5% confidence interval (CI) for the hazard ratio (HR) was less than the predefined limit of 1.23 (the non-inferiority margin)] were therefore applied to OS as well.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="574.0" lower_limit="537" upper_limit="592"/>
                    <measurement group_id="O2" value="551.0" lower_limit="528" upper_limit="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented together with the 97.5% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1921</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>Baseline until disease progression or death, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.0" lower_limit="230" upper_limit="257"/>
                    <measurement group_id="O2" value="285.0" lower_limit="271" upper_limit="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                    <measurement group_id="O2" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of XELOX with/without bevacizumab to FOLFOX-4 with/without bevacizumab was tested by the pair of hypotheses - H0: OR(XELOX/XELOX+P/XELOX+BV)/(FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV) &lt;/= 0.66 versus H1: OR(XELOX/XELOX+P/XELOX+BV)/(FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV) &gt; 0.66, where OR denotes Odds ratio.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The analysis was based on the two-sided 97.5% confidence interval for OR(XELOX/XELOX+P/XELOX+BV)/(FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV). Non-inferiority of XELOX with/without bevacizumab to FOLFOX-4 with/without bevacizumab was concluded if the lower limit of this confidence interval is above 0.66.</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of adding bevacizumab to chemotherapy was tested as follows - H0: OR(FOLFOX-4+BV/XELOX+BV)/(FOLFOX-4+P/XELOX+P) &lt;/= 1.0 versus H1: OR(FOLFOX-4+BV/XELOX+BV)/(FOLFOX-4+P/XELOX+P) &gt; 1.0. The test used a two-sided significance level of 2.5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3091</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of XELOX with/without bevacizumab to FOLFOX-4 with/without bevacizumab was tested by the pair of hypotheses - H0: OR(XELOX/XELOX+P/XELOX+BV)/(FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV) &lt;/= 0.66 versus H1: OR(XELOX/XELOX+P/XELOX+BV)/(FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV) &gt; 0.66</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The analysis was based on the two-sided 97.5% confidence interval for OR(XELOX/XELOX+P/XELOX+BV)/(FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV). Non-inferiority of XELOX with/without bevacizumab to FOLFOX-4 with/without bevacizumab shall be concluded if the lower limit of this confidence interval is above 0.66.</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of adding bevacizumab to chemotherapy was tested as follows - H0: OR(FOLFOX-4+BV/XELOX+BV)/(FOLFOX 4+P/XELOX+P) &lt;/= 1.0 versus H1: OR(FOLFOX-4+BV/XELOX+BV)/(FOLFOX-4+P/XELOX+P) &gt; 1.0. The test used a two-sided significance level of 2.5%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9887</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The safety population included all participants who were randomized and received at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.</description>
          <population>The safety population included all participants who were randomized and received at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="990"/>
                <count group_id="O2" value="1008"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.0" lower_limit="183" upper_limit="202"/>
                    <measurement group_id="O2" value="179.0" lower_limit="171" upper_limit="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-treatment Approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.0" lower_limit="182" upper_limit="200"/>
                    <measurement group_id="O2" value="176.0" lower_limit="170" upper_limit="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General approach: HRs and 97.5% confidence interval were reported for treatment arm A (XELOX/XELOX+P/XELOX+BV) versus treatment arm B (FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal statistical testing was done.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>On-treatment Approach: HRs and 97.5% confidence interval were reported for treatment arm A (XELOX/XELOX+P/XELOX+BV) versus treatment arm B (FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Fewer events were expected in analyses using the on-treatment approach than in the analyses using the general approach, thus leading to reduced power.Therefore, no formal statistical testing was performed.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The safety population included all participants who were randomized and received at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.</description>
          <population>The safety population included all participants who were randomized and received at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
                <count group_id="O2" value="694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.0" lower_limit="176" upper_limit="198"/>
                    <measurement group_id="O2" value="209.0" lower_limit="199" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-treatment Approach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.0" lower_limit="175" upper_limit="196"/>
                    <measurement group_id="O2" value="208.0" lower_limit="198" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General approach: Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>On treatment approach: Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>Week 1 to Week 54</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25-30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 31-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37-42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49-54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>Week 1 to Week 54</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25-30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 31-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37-42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49-54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.0" lower_limit="225" upper_limit="256"/>
                    <measurement group_id="O2" value="226.0" lower_limit="211" upper_limit="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HRs and 97.5% confidence interval were reported for treatment arm A (XELOX/XELOX+P/XELOX+BV) versus treatment arm B (FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal statistical testing was performed for duration of overall response.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone</title>
        <description>Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone</title>
          <description>Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.0" lower_limit="217" upper_limit="240"/>
                    <measurement group_id="O2" value="257.0" lower_limit="241" upper_limit="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0307</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
        <description>For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Folfox-4: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin (given on day 1).
Folfox-4+P: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).</description>
          </group>
          <group group_id="O2">
            <title>XELOX/XELOX+P/XELOX+BV</title>
            <description>Participants from the initial 2-arm part and the 2x2 factorial part of the study including the following groups -
Xelox: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin (given on day 1).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4</title>
          <description>For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.</description>
          <population>The EPP excluded participants from the ITT who had violated major protocol inclusion or exclusion criteria or participants who were randomized and did not receive at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="937"/>
                <count group_id="O2" value="967"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.0" lower_limit="196" upper_limit="403"/>
                    <measurement group_id="O2" value="589.0" lower_limit="270">The estimate is Not Available due to insufficient follow-up time to estimate the missing parameter.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HRs and 97.5% confidence interval were reported for treatment arm A (XELOX/XELOX+P/XELOX+BV) versus treatment arm B (FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal statistical testing was done.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.35</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
        <description>For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
        <time_frame>From baseline until disease progression/recurrence, approximately 2 years 6 months</time_frame>
        <population>The ITT population included all randomized participants who provided written informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX-4+P/XELOX+P</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+P: Participants received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and placebo control for bevacizumab (both given on day 1 every 2 weeks).
Xelox+P: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and placebo (P) control for bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX-4+BV/XELOX+BV</title>
            <description>Participants from the 2x2 factorial part of the study including the following groups -
Folfox-4+BV: Participants who received 2-week cycles of infused leucovorin, bolus injection fluorouracil and continuous infusion fluorouracil (given on days 1 and 2), combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 2 weeks).
Xelox+BV: Capecitabine was administered as an oral twice-daily outpatient intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) combined with intravenous oxaliplatin and intravenous bevacizumab (both given on day 1 every 3 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone</title>
          <description>For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.</description>
          <population>The ITT population included all randomized participants who provided written informed consent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.0" lower_limit="228">The estimate is Not Available due to insufficient follow-up time to estimate the missing parameter.</measurement>
                    <measurement group_id="O2" value="386.0" lower_limit="133" upper_limit="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing for superiority was based on the stratified log-rank test and used a two-sided significance level of 2.5%.The hazard ratio (HR) of bevacizumab in combination with chemotherapy versus chemotherapy alone [HR(FOLFOX-4+P/XELOX+P)/(FOLFOX-4+BV/XELOX+BV)] was presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8207</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>7.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 2 years 6 months</time_frame>
      <desc>Serious adverse events (SAEs) and non-serious adverse events were reported for members of the safety population, which included all participants were randomized and received at least one dose of capecitabine, 5-FU, oxaliplatin, or bevacizumab/placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Xelox</title>
          <description>Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="E2">
          <title>Folfox-4</title>
          <description>Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="E3">
          <title>Xelox+P</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for bevacizumab (BV) [volume equivalent to 7.5 mg/kg BV] over 30 to 90 minutes followed by oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="E4">
          <title>Folfox-4+P</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for BV (volume equivalent to 5 mg/kg BV) over 30 to 90 minutes followed by oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="E5">
          <title>Xelox+BV</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 7.5 mg/kg over 30 to 90 minutes followed by oxaliplatin 130 mg/m^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
        <group group_id="E6">
          <title>Folfox-4+BV</title>
          <description>Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 5 mg/kg over 30 to 90 minutes followed by oxaliplatin 85 mg/m^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m^2 iv for 2 hours followed by fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="128" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="131" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="146" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vascular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Stomatitis all</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Intestinal functional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Enterocolonic fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Intestinal ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Toxic dilatation of intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hepatitis Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anal fistula infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Stent occlussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Device migration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Failure to anastomose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Vascular graft occlussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>International normalized ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Blood bilirubin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Endoscopic retrograde cholangiopancreatography</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypokalaemia`</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Tumor haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Metastases to ovary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Encephalophathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemmorhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dysaesthesia pharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Alveolitis fibrosing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Angioneurotic oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Vascular purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Ileostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Poor venous access</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="310" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="310" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="330" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="331" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="348" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="335" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="198" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="187" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="44" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="197" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="210" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="218" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="209" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="204" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="230" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="215" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="127" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="160" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="127" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Stomatitis All</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="130" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="101" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="141" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="68" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="101" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="85" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="140" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="133" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="135" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="97" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="82" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Temperature Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="109" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="96" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="127" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="133" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="135" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="72" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="61" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="62" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="107" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dysaesthesia pharynx</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="138" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="63" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="313"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="336"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 61 6878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

